Dianthus Therapeutics(NASDAQ) DNTH

Market Cap$4.92BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2023)+700%
5 Year-23%
1 Year+152%
1 Month-19%
Premium Feature
Moneyball Superscore
66/100
$83.65
-4.99%
-4.39Today
Dianthus Therapeutics last closing stock price
MetricPriceDate
Last closeUSD 88.042026-10-05
Dianthus Therapeutics stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+0.24%USD 87.832026-09-28
1 month-18.56%USD 108.102026-09-04
3 month-8.06%USD 95.762026-07-07
Year to date+113.64%USD 41.212025-12-31
1 year+151.97%USD 34.942025-10-03
3 year+628.21%USD 12.092023-10-06
5 year-23.36%USD 114.882021-10-06
Since inception+700.36%USD 11.002023-09-12

Dianthus Therapeutics Financials at a Glance

Market Cap

$4.92BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$1.90

Net Income (TTM)

-$192.25

EPS (TTM)

-$4.15

P/E Ratio

-21.20

Dividend

$0.00

Beta (Volatility)

1.04 (Average)

Price

$83.65

Volume

419,009.994

Open

$88.58

Previous Close

$88.04

Daily Range

$83.19 - $88.58

52-Week Range

$32.22 - $117.88

Estimated Earnings Date

N/A

DNTH News

SellAlert-Blue.png

Dianthus Therapeutics Is Up 320% in a Year. One Major Investor Just Reduced Its Stake but Still Seems Bullish

Jonathan PoncianoMay 18, 2026
f5acfa2370b69ef05efd688fbbc9e56e546c0092-1401x1251.png

Why This Fund Just Made a $55 Million Bet on Dianthus Amid a 350% Stock Rally

Jonathan PoncianoMay 17, 2026
SellAlert-Green.png

Dianthus Therapeutics' (DNTH) CFO Sold 8,224 Shares for $739,000

Cory RenauerApr 19, 2026
SellAlert-Blue.png

Dianthus Therapeutics CFO Sells $9.5 Million in Stock

Pamela KockApr 6, 2026
SellAlert-Red.png

Biotech Stock Jumps 288% Amid Massive Raise as One Early Backer Reports $14 Million Exit

Jonathan PoncianoMar 18, 2026
SellAlert-Red.png

Dianthus CFO Sells 20,000 Shares for $903,600 After Massive Year-End Run

Sarah SidlowJan 7, 2026
Foolcom-Featured.png

Dianthus (DNTH) Q2 Loss Widens 80%

Motley Fool Markets TeamAug 7, 2025

DNTH: Motley Fool Moneyball Superscore

66

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Dianthus Therapeutics

Dianthus Therapeutics, Inc. is a clinical-stage biotechnology company. It designs and delivers novel, monoclonal antibodies with improved selectivity and potency over existing complement therapies. The company was founded on June 17, 2015 and is headquartered in New York, NY.

Industry

Biotechnology

Sector

Health Care

Employees

92

CEO

Marino Garcia, MBA

Website

dianthustx.com

DNTH Financials

Key Financial Metrics (TTM)

Gross Margin

N/A

Operating Margin

N/A

Net Income Margin

N/A

Return on Equity

-26.07%

Return on Capital

N/A

Return on Assets

N/A

Earnings Yield

-4.72%

Dividend Yield

0.00%

Payout Ratio

N/A

Stock Overview

Market Cap

$4.92BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

55.93M

Volume

419.01K

Avg. Volume

816.68K

Financials (TTM)

Gross Profit

N/A

Operating Income

N/A

EBITDA

N/A

Operating Cash Flow

N/A

Capital Expenditure

N/A

Free Cash Flow

N/A

Cash & ST Invst.

N/A

Total Debt

N/A

Dianthus Therapeutics Performance Analysis

Dianthus Therapeutics annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 6,417,000N/A
20232023-12-31USD 2,826,000-56.0%
20242024-12-31USD 6,235,000120.6%
20252025-12-31USD 2,036,000-67.3%
Dianthus Therapeutics annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -32.5757.3%
20232023-12-31USD -8.45-74.1%
20242024-12-31USD -2.55-69.8%
20252025-12-31USD -4.2064.8%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

$0.76

+3.9%

Gross Profit

$0.65

+7.0%

Gross Margin

85.94%

+1.8%

Market Cap

$4.92BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$57.92

N/A

Employees

92

N/A

Net Income

-$50.22

+1.6%

EBITDA

-$61.38

+1.8%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

$111.84

+667.7%

Total Debt

$1.29

+1.0%

Accounts Receivable

$0.31

+2.2%

Inventory

$0.00

N/A

Long Term Debt

$0.91

+0.8%

Short Term Debt

$0.37

+1.8%

Return on Assets

-24.98%

+0.8%

Return on Invested Capital

-32.45%

+0.9%

Free Cash Flow

-$49.16

+2.1%

Operating Cash Flow

-$48.98

+2.1%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
^GSPCS&P 500
$7,777.74+0.01%
^DJIDJI
$51,304.21+0.00%
^IXICNASDAQ
$27,461.27+0.01%
BTCBitcoin
$85,510.00+0.00%

Questions About DNTH

What is the current price of Dianthus Therapeutics?

Dianthus Therapeutics is trading at $83.19 per share.

What is the 52-week range for Dianthus Therapeutics?

Over the past 52 weeks, Dianthus Therapeutics has traded between $32.22 and $117.88.

How much debt does Dianthus Therapeutics have?

As of the most recent reporting period, Dianthus Therapeutics reported total debt of $1.29M.

How much cash does Dianthus Therapeutics have on hand?

Dianthus Therapeutics reported $110.55M in cash and cash equivalents in its most recent financial results.

What is Dianthus Therapeutics’s dividend yield?

Dianthus Therapeutics does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services